AHA: HRSA Tells J&J It Can’t Replace 340B Discounts With New Rebate Approach

The Health Resources and Services Administration warned Johnson & Johnson on Friday (Aug. 23) it can’t use rebates to replace upfront discounts for drugs it provides under the 340B discount program, according to the American Hospital Association, which had asked HRSA whether J&J’s new 340B model for its popular blood clot treatment Xarelto and psoriasis and Crohn’s treatment Stelara passed muster. Both drugs separately face lower Medicare Part D prices in 2026 as a result of the first round of...